Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of LTC004 monotherapy in patients with locally advanced or metastatic sarcoma after failure of standard therapy
CTR20241468Phase 2Active
- Sponsor
- Beijing Zhidao Biotechnology
- Start
- Apr 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of LTC004 in Bone and soft tissue sarcoma, sponsored by Beijing Zhidao Biotechnology. Started Apr 2024; status: active.
02
Drugs
LTC004
03
Conditions
Bone and soft tissue sarcoma
Beyond the preview
Go deeper on CTR20241468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241468.